Case number 1:22-cv-01040
Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 17, 2024 | 219 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Plaintiffs' Expert Thomas W. Muir, Ph.D. and (2) Rebuttal Expert Report of Plaintiffs' Expert Michael E. Trautmann, M.D. Regarding U.S. Patent No. 8,129,343 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/17/2024) (10) |
| Jun 3, 2024 | 216 | NOTICE OF SERVICE of (i) Responsive Expert Report of Randall Zusman, M.D. [CONFIDENTIAL]; and, (ii) the accompanying production bates labeled SEMA(DMS)_0000001-SEMA(DMS)_0000055 filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd..(Gattuso, Dominick) (Entered: 06/03/2024) (3) |
| Jun 3, 2024 | 217 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Michael E. Trautmann, M.D. Regarding Validity of U.S. Patent No. 10,335,462 and (2) Rebuttal Expert Report of Patrick Sinko, Ph.D. Regarding Validity of U.S. Patent No. 10,335,462 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/03/2024) (10) |
| Jun 3, 2024 | 218 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Dr. Herbert Lin Regarding U.S. Patent Nos. 8,129,343 and 10,335,462, (2) Rebuttal Expert Report of Virginia W. Cornish, Ph.D., on Objective Indicia of U.S. Patent 8,129,343, (3) Responsive Expert Report of Arthur Z. Schwartzbard, M.D., F.A.C.C., (4) Rebuttal Expert Report of Dr. Allen Spiegel Regarding Invalidity of U.S. Patent No. 10,335,462, (5) Rebuttal Expert Report of Dr. George Grunberger Regarding Invalidity of U.S. Patent No. 10,335,462, and (6) Expert Report of DeForest McDuff, Ph.D. filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/03/2024) (3) |
| May 31, 2024 | 214 | Joint STIPULATION and [Proposed] Order Amending Certain Expert Discovery Deadlines by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/31/2024) (5) |
| May 31, 2024 | 215 | SO ORDERED, re (298 in 1:22-cv-00294-CFC, 214 in 1:22-cv-01040-CFC, 342 in 1:22-md-03038-CFC) Stipulation Amending Certain Expert Discovery Deadlines, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/31/2024. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 05/31/2024) (5) |
| May 28, 2024 | 213 | Pro Hac Vice Fee - Credit Card Payment received for Aaron E. Schindler. ( re 212 MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler )( Payment of $ 50, receipt number ADEDC-4416980).(Stamoulis, Stamatios) (Entered: 05/28/2024) (0) |
| May 27, 2024 | 212 | MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/27/2024) (4) |
| May 17, 2024 | 211 | NOTICE OF SERVICE of Opening Expert Report of Virginia W. Cornish, Ph.D. Regarding Invalidity of U.S. Patent 8,129,343 filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..(Farnan, Kelly) (Entered: 05/17/2024) (3) |
| May 14, 2024 | 207 | STIPULATION and [Proposed] Order Amending Certain Case Deadlines - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/14/2024) (6) |
| May 14, 2024 | 208 | MOTION for Pro Hac Vice Appearance of Attorney Kyu Yun Kim of FENWICK & WEST LLP - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/14/2024) (7) |
| May 14, 2024 | 209 | Pro Hac Vice Fee - Credit Card Payment received for Kyu Yun Kim of FENWICK & WEST LLP. ( re 208 MOTION for Pro Hac Vice Appearance of Attorney Kyu Yun Kim of FENWICK & WEST LLP )( Payment of $ 50, receipt number ADEDC-4406779).(Murray, Travis) (Entered: 05/14/2024) (0) |
| May 14, 2024 | 210 | SO ORDERED, re (335 in 1:22-md-03038-CFC, 207 in 1:22-cv-01040-CFC, 293 in 1:22-cv-00294-CFC) STIPULATION and Order Amending Certain Case Deadlines. ORDER Resetting Scheduling Order Deadlines: ( A Final Pretrial Conference is set for 10/29/2024 at 10:00 AM in Courtroom 4B before Judge Colm F. Connolly., Expert Discovery due by 8/16/2024., Proposed Pretrial Order due by 10/8/2024.) SEE ORDER FOR FURTHER DETAILS. Signed by Judge Colm F. Connolly on 5/14/2024. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(nmf) (Entered: 05/14/2024) (6) |
| Apr 29, 2024 | 206 | SO ORDERED, re (205 in 1:22-cv-01040-CFC) STIPULATION TO EXTEND TIME to serve rebuttal expert reports to May 24, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc., (289 in 1:22-cv-00294-CFC, 331 in 1:22-md-03038-CFC) STIPULATION TO EXTEND TIME to serve rebuttal expert reports to May 24, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 4/29/2024. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(nmf) (Entered: 04/29/2024) (6) |
| Apr 26, 2024 | 205 | STIPULATION TO EXTEND TIME to serve rebuttal expert reports to May 24, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 04/26/2024) (6) |
| Mar 20, 2024 | 202 | NOTICE OF SERVICE of the Opening Expert Report of Zhaohui Sunny Zhou, Ph.D. Regarding Invalidity of U.S. Patent 8,129,343 filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceuticals Industries Inc., Sun Pharmaceutical Industries Inc..(Metzler, Sara) (Entered: 03/20/2024) (3) |
| Mar 20, 2024 | 203 | NOTICE OF SERVICE of (1) Opening Expert Report of Plaintiffs' Expert John B. Buse, M.D., Ph.D. Regarding Objective Indicia, (2) Opening Expert Report of Plaintiffs' Expert Thomas W. Muir, Ph.D., (3) Opening Expert Report of Plaintiffs' Expert Mikhail N. Kosiborod, M.D., (4) Opening Expert Report of Plaintiffs' Expert Lee M. Kaplan, M.D., Ph.D., (5) Opening Expert Report of Plaintiffs' Expert Matthew R. Weir, M.D., (6) Opening Expert Report of Christopher A. Vellturo, Ph.D., (7) Opening Expert Report of Plaintiffs' Expert John B. Buse, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 10,335,462 by Mylan Pharmaceuticals Inc., (8) Opening Expert Report of Plaintiffs' Expert Patrick J. Sinko, Ph.D. Regarding Infringement by Defendants Mylan Pharmaceuticals Inc., (9) Opening Expert Report of Plaintiffs' Expert John B. Buse, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 10,335,462 by Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries Inc., (10) Opening Expert Report of Plaintiffs' Expert William R. Roush, Ph.D. Regarding Infringement by Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc., (11) Opening Expert Report of Plaintiffs' Expert Patrick J. Sinko, Ph.D. Regarding Infringement by Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc., (12) Opening Expert Report of Plaintiffs' Expert John B. Buse, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 10,335,462 by Rio Biopharmaceuticals Inc. and EMS S/A, (13) Opening Expert Report of Plaintiffs' Expert William R. Roush, Ph.D. Regarding Infringement by Defendants Rio Pharmaceuticals Incorporated and EMS S/A, (14) Opening Expert Report of Plaintiffs' Expert Patrick J. Sinko, Ph.D. Regarding Infringement by Defendants Rio Biopharmaceuticals Inc. and EMS S/A, (15) Opening Expert Report of Plaintiffs' Expert John B. Buse, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 10,335,462 by Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc., (16) Opening Expert Report of Plaintiffs' Expert Patrick J. Sinko, Ph.D. Regarding Infringement by Defendants Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/20/2024) (15) |
| Mar 20, 2024 | 204 | NOTICE OF SERVICE of (1) Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, (2) Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, and (3) Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/20/2024) (2) |
| Mar 15, 2024 | 201 | SO ORDERED, re (200 in 1:22-cv-01040-CFC, 324 in 1:22-md-03038-CFC, 282 in 1:22-cv-00294-CFC) STIPULATION TO EXTEND TIME Certain Deadlines Related to Experts to See Stipulation, filed by Mylan Pharmaceuticals Inc. Reset Scheduling Order Deadlines: Opening Expert Reports due by 3/19/2024. Rebuttal Expert Reports due by 4/26/2024. Expert Discovery due by 7/3/2024. Signed by Judge Colm F. Connolly on 3/15/2024. Associated Cases: 1:22-cv-00294-CFC, 1:22-cv-01040-CFC, 1:22-md-03038-CFC (kmd) (Entered: 03/15/2024) (5) |
| Mar 14, 2024 | 200 | STIPULATION TO EXTEND TIME Certain Deadlines Related to Experts to See Stipulation - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 03/14/2024) (5) |
| Mar 11, 2024 | 199 | SO ORDERED, re (198 in 1:22-cv-01040-CFC, 320 in 1:22-md-03038-CFC) Stipulation Regarding the '343, '122, '383, and '953 Patents, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/11/2024. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 03/11/2024) (7) |
| Mar 8, 2024 | 198 | STIPULATION and [Proposed] Order Regarding the '343, '122, '383, and '953 Patents - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/08/2024) (7) |
| Mar 6, 2024 | 197 | NOTICE OF SERVICE of Plaintiffs' Responses to Defendant's Third Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,920,383 and 9,775,953 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/06/2024) (7) |
| Mar 5, 2024 | 196 | NOTICE OF SERVICE of Defendants Second Supplemental Noninfringement Contentions filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/05/2024) (2) |
| Feb 29, 2024 | 194 | STIPULATION TO EXTEND TIME to Supplement Noninfringement Contentions and Responses to Invalidity Contentions for the '953 and '383 patents to March 5, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 02/29/2024) (3) |
| Feb 29, 2024 | 195 | SO ORDERED, re (315 in 1:22-md-03038-CFC, 276 in 1:22-cv-00294-CFC, 194 in 1:22-cv-01040-CFC) STIPULATION TO EXTEND TIME to Supplement Noninfringement Contentions and Responses to Invalidity Contentions for the '953 and '383 patents to March 5, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 2/29/2024. Associated Cases: 1:22-cv-00294-CFC, 1:22-cv-01040-CFC, 1:22-md-03038-CFC (kmd) (Entered: 02/29/2024) (3) |
| Feb 21, 2024 | 193 | SO ORDERED, re (192 in 1:22-cv-01040-CFC, 312 in 1:22-md-03038-CFC, 273 in 1:22-cv-00294-CFC) STIPULATION TO EXTEND TIME for the Deadline to Supplement Noninfringement Contentions and Responses to Invalidity Contentions for the 953 and 383 patents to February 29, 2024, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 2/21/2024. Associated Cases: 1:22-cv-01040-CFC, 1:22-cv-00294-CFC, 1:22-md-03038-CFC(kmd) (Entered: 02/21/2024) (3) |
| Feb 20, 2024 | 192 | STIPULATION TO EXTEND TIME for the Deadline to Supplement Noninfringement Contentions and Responses to Invalidity Contentions for the 953 and 383 patents to February 29, 2024 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 02/20/2024) (3) |
| Feb 12, 2024 | 191 | NOTICE OF SERVICE of Novo Nordisk's Responses to Defendants' Second Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; and 10,335,462 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/12/2024) (11) |
| Feb 9, 2024 | 190 | STIPULATION TO EXTEND TIME of Certain Deadlines Related to Experts to See Stipulation - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 02/09/2024) (3) |
| Feb 6, 2024 | 189 | SO ORDERED, re (300 in 1:22-md-03038-CFC, 186 in 1:22-cv-01040-CFC) STIPULATION TO EXTEND TIME Fact Discovery Cutoff to February 14, 2024, filed by Mylan Pharmaceuticals Inc. Reset Scheduling Order Deadlines: Fact Discovery completed by 2/14/2024. Signed by Judge Colm F. Connolly on 2/6/2024. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 02/06/2024) (3) |
| Feb 1, 2024 | 187 | NOTICE OF SERVICE of Defendants' Third Supplemental Invalidity Contentions (with Exhibits D and E) [CONFIDENTIAL] filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd..(Gattuso, Dominick) (Entered: 02/01/2024) (2) |
| Feb 1, 2024 | 188 | NOTICE OF SERVICE of Plaintiffs' Amended Infringement Contentions as to Mylan Pharmaceuticals Inc. Regarding the '383 and '953 Patents - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/01/2024) (4) |
| Jan 31, 2024 | 186 | STIPULATION TO EXTEND TIME Fact Discovery Cutoff to February 14, 2024 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 01/31/2024) (3) |
| Jan 19, 2024 | 185 | NOTICE OF SERVICE of Plaintiffs' Final Election of Asserted Claims for U.S. Patent No. 8,950,383 and U.S. Patent No. 9,775,953 to Defendant Mylan Pharmaceuticals Inc. - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/19/2024) (5) |
| Jan 16, 2024 | 183 | NOTICE OF SERVICE of Plaintiffs' Amended Infringement Contentions as to Mylan Pharmaceuticals Inc. Regarding the '343, '122, and '462 Patents - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/16/2024) (5) |
| Jan 16, 2024 | 184 | NOTICE OF SERVICE of Defendants' Final Disclosure of Prior Art regarding the 383 and 953 Patents [CONFIDENTIAL] filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd..(Gattuso, Dominick) (Entered: 01/16/2024) (2) |
| Jan 10, 2024 | 179 | STIPULATION and [Proposed] Order Regarding Authenticity and Business Record Status of Documents (as to Defendant Mylan Pharmaceuticals Inc.) - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 01/10/2024) (9) |
| Jan 10, 2024 | 180 | SO ORDERED, re (252 in 1:22-cv-00294-CFC, 285 in 1:22-md-03038-CFC, 179 in 1:22-cv-01040-CFC) Stipulation Regarding Authenticity and Business Record Status of Documents (as to Defendant Mylan Pharmaceuticals Inc.), filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 1/10/2024. Associated Cases: 1:22-cv-00294-CFC, 1:22-cv-01040-CFC, 1:22-md-03038-CFC (kmd) (Entered: 01/10/2024) (9) |
| Jan 10, 2024 | 181 | NOTICE OF SERVICE of Defendants' Supplemental Preliminary Disclosure of Prior Art Regarding the '383 and '953 Patents filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd..(Gattuso, Dominick) (Entered: 01/10/2024) (2) |
| Jan 10, 2024 | 182 | NOTICE OF SERVICE of Plaintiffs' Second Supplemental Disclosure of Asserted Patents and Claims as to MPI Regarding U.S. Patent Nos. 8,920,383 and 9,775,953 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/10/2024) (5) |
| Dec 18, 2023 | 178 | SO ORDERED, re 177 STIPULATION TO EXTEND TIME for Certain Fact Discovery to January 31, 2024, filed by Mylan Pharmaceuticals Inc. Reset Scheduling Order Deadlines: Fact Discovery completed by 1/31/2024. Signed by Judge Colm F. Connolly on 12/18/2023. (kmd) (Entered: 12/18/2023) (3) |
| Dec 15, 2023 | 177 | STIPULATION TO EXTEND TIME for Certain Fact Discovery to January 31, 2024 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 12/15/2023) (3) |
| Dec 13, 2023 | 175 | STIPULATION and [Proposed] Order Further Amending Scheduling Order by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd.. (Gattuso, Dominick) (Entered: 12/13/2023) (5) |
| Dec 13, 2023 | 176 | SO ORDERED, re (277 in 1:22-md-03038-CFC, 244 in 1:22-cv-00294-CFC, 175 in 1:22-cv-01040-CFC) Stipulation Further Amending Scheduling Order, filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd. Signed by Judge Colm F. Connolly on 12/13/2023. Associated Cases: 1:22-cv-00294-CFC, 1:22-cv-01040-CFC, 1:22-md-03038-CFC (kmd) (Entered: 12/13/2023) (5) |
| Dec 11, 2023 | 174 | SUPPLEMENTAL CLAIM CONSTRUCTION ORDER re (274 in 1:22-md-03038-CFC, 173 in 1:22-cv-01040-CFC, 241 in 1:22-cv-00294-CFC) Letter, ORDER, terminating Deadlines/Hearings: The Supplemental Markman briefing deadlines and the January 11, 2024 Supplemental Markman hearing are vacated. Signed by Judge Colm F. Connolly on 12/11/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(nmf) (Entered: 12/11/2023) (4) |
| Dec 8, 2023 | 173 | Letter to The Honorable Colm F. COnnolly from Travis Murray regarding remaining claim construction terms in dispute. (Attachments: # 1 [Proposed] Supplemental Claim Construction Order)(Murray, Travis) (Entered: 12/08/2023) (0) |
| Dec 7, 2023 | 172 | NOTICE to Take Deposition of Thomas Kruse Hansen on December 8, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 12/07/2023) (5) |
| Dec 1, 2023 | 171 | SO ORDERED, re (267 in 1:22-md-03038-CFC, 170 in 1:22-cv-01040-CFC, 235 in 1:22-cv-00294-CFC) Stipulation Amending Scheduling Order, filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd. Resetting Scheduling Order Deadlines: Fact Discovery completed by 12/15/2023. Opening Expert Reports due by 3/1/2024. Rebuttal Expert Reports due by 4/5/2024. Expert Discovery due by 6/7/2024. Signed by Judge Colm F. Connolly on 12/1/2023. Associated Cases: 1:22-cv-00294-CFC, 1:22-cv-01040-CFC, 1:22-md-03038-CFC(kmd) (Entered: 12/01/2023) (7) |
| Nov 30, 2023 | 170 | STIPULATION Amending Scheduling Order with [Proposed] Order by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd.. (Gattuso, Dominick) (Entered: 11/30/2023) (7) |
| Nov 20, 2023 | 168 | SO ORDERED, re (167 in 1:22-cv-01040-CFC, 261 in 1:22-md-03038-CFC, 230 in 1:22-cv-00294-CFC) STIPULATION TO EXTEND TIME for Supplemental Claim Construction Briefs and Expert Declarations to December 11, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Deadlines for Claim Construction Briefing and Markman Hearing: Joint Claim Construction Brief due by 12/11/2023. Signed by Judge Colm F. Connolly on 11/20/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 11/20/2023) (4) |
| Nov 20, 2023 | 169 | NOTICE to Take Deposition of Stephanie DeChiaro on November 21, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/20/2023) (5) |
| Nov 17, 2023 | 167 | STIPULATION TO EXTEND TIME for Supplemental Claim Construction Briefs and Expert Declarations to December 11, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/17/2023) (4) |
| Nov 14, 2023 | 166 | MOTION for Pro Hac Vice Appearance of Attorney Maria A. Stubbings - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 11/14/2023) (4) |
| Nov 13, 2023 | 165 | NOTICE to Take Deposition of Vanessa Costain on November 15, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/13/2023) (5) |
| Nov 3, 2023 | 164 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Third Set of Requests for Production (Nos. 29-32) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/03/2023) (11) |
| Nov 2, 2023 | 163 | NOTICE OF SERVICE of (1) Plaintiffs' Responses and Objections to Defendants' Second Set of Requests for Production (Nos. 24-28); (2) Plaintiffs' Responses and Objections to Defendants' Second Set of Interrogatories (Nos. 5-7); and (3) Plaintiffs' Responses and Objections to Defendants' First Set of Joint Requests for Admission to Plaintiffs (Nos. 1-25) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/02/2023) (11) |
| Oct 31, 2023 | 161 | STIPULATION and [Proposed] Order Regarding Trial of the MPI Ozempic Litigation - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/31/2023) (4) |
| Oct 31, 2023 | 162 | SO ORDERED, re (161 in 1:22-cv-01040-CFC, 244 in 1:22-md-03038-CFC) Stipulation Regarding Trial of the MPI Ozempic Litigation, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/31/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 10/31/2023) (4) |
| Oct 25, 2023 | 160 | NOTICE to Take Deposition of Jesper Lau on October 26, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 10/25/2023) (5) |
| Oct 20, 2023 | 159 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding expert testimony - re (157 in 1:22-md-03038-CFC, 157 in 1:22-md-03038-CFC) Order,, Set Deadlines/Hearings,. (Murray, Travis) (Entered: 10/20/2023) (2) |
| Oct 19, 2023 | 158 | SO ORDERED, re (239 in 1:22-md-03038-CFC, 157 in 1:22-cv-01040-CFC, 213 in 1:22-cv-00294-CFC) Stipulation Extending Deadline for Certain Fact Discovery Deadlines, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/19/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 10/19/2023) (5) |
| Oct 18, 2023 | 157 | Joint STIPULATION and [Proposed] Order Extending Deadline for Certain Fact Discovery Deadlines - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/18/2023) (5) |
| Oct 17, 2023 | 156 | NOTICE to Take Deposition of Nitin Bhattad on October 31, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 10/17/2023) (4) |
| Oct 6, 2023 | 155 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/06/2023) (11) |
| Sep 29, 2023 | 154 | MOTION for Pro Hac Vice Appearance of Attorney David L. Anstaett - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 09/29/2023) (4) |
| Sep 28, 2023 | 152 | Joint STIPULATION and [Proposed] Order of Dismissal as to Mylan Pharmaceuticals Inc. Regarding the '833, '969, '002, '239, '154, '180, '611, '757, '155, '616, '652, '063, '679, '443, and '363 Patents by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 09/28/2023) (5) |
| Sep 28, 2023 | 153 | SO ORDERED, re (152 in 1:22-cv-01040-CFC, 232 in 1:22-md-03038-CFC) Stipulation of Dismissal as to Mylan Pharmaceuticals Inc. Regarding the '833, '969, '002, '239, '154, '180, '611, '757, '155, '616, '652, '063, '679, '443, and '363 Patents, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 9/28/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 09/28/2023) (5) |
| Sep 25, 2023 | 151 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/25/2023) (11) |
| Sep 20, 2023 | 148 | MOTION for Pro Hac Vice Appearance of Attorney Silvia M. Medina - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 09/20/2023) (9) |
| Sep 20, 2023 | 149 | NOTICE OF SERVICE of Plaintiffs' Fourth Set of Requests for the Production of Documents and Things (Nos. 169-181) Directed to Defendant Mylan Pharmaceuticals Inc. - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/20/2023) (5) |
| Sep 20, 2023 | 150 | NOTICE OF SERVICE of (1) Plaintiffs' First Set of Collective Requests for Admission to Defendants (Nos. 1-24), (2) Plaintiffs' Fourth Set of Collective Interrogatories to Defendants (Nos. 15-16), (3) Plaintiffs' First Set of Requests for Admission to Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (Nos. 1-69), (4) Plaintiffs' First Set of Requests for Admission to Defendant Alvogen, Inc. (Nos. 1-56), (5) Plaintiffs' First Set of Requests for Admission to Defendant Mylan Pharmaceuticals, Inc. (Nos. 1-82), (6) Plaintiffs' First Set of Requests for Admission to Defendants Rio Biopharmaceuticals Inc. and EMS S/A (Nos. 1-48), (7) Plaintiffs' First Set of Requests for Admission to Defendants Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (Nos. 1-58), and (8) Plaintiffs' First Set of Requests for Admission to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. (Nos. 1-61) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/20/2023) (17) |
| Sep 19, 2023 | 145 | NOTICE OF SERVICE of (i) Defendants' First Set of Joint Requests for Admission to Plaintiffs (Nos. 1-25); and, (ii) Defendants' Second Set of Interrogatories to Plaintiffs (Nos. 5-7) filed by Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd..(Gattuso, Dominick) (Entered: 09/19/2023) (3) |
| Sep 19, 2023 | 146 | NOTICE to Take Deposition of 30(b)(6) Corporate Representative filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 09/19/2023) (7) |
| Sep 19, 2023 | 147 | NOTICE OF SERVICE of (1) Defendants Second Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) and (2) Defendants Second Set of Requests for Production to Plaintiffs filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 09/19/2023) (2) |
| Sep 14, 2023 | 144 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Objections and Responses to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 09/14/2023) (2) |
| Sep 13, 2023 | 143 | MOTION for Pro Hac Vice Appearance of Attorney Vanessa Park-Thompson, Allie Cohen Dolloff, Ryan A. Haddad, Retley G. Locke Jr., Michael Yoon, Michelle E. Irwin and Adeline Miller - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 09/13/2023) (14) |
| Sep 7, 2023 | 138 | NOTICE to Take Deposition of Beth Britton (Mylan) on September 25, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/07/2023) (4) |
| Sep 7, 2023 | 139 | NOTICE to Take Deposition of Dave Mitchell (Mylan) on September 26, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/07/2023) (4) |
| Sep 7, 2023 | 140 | NOTICE to Take Deposition of Claire McDiarmid (Mylan) on September 27, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/07/2023) (4) |
| Sep 7, 2023 | 141 | NOTICE to Take Deposition of Dilip Jayagopal (Mylan) on September 28, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/07/2023) (4) |
| Sep 7, 2023 | 142 | NOTICE to Take Deposition of Kuntal Maiti (Mylan) on September 29, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/07/2023) (4) |
| Sep 5, 2023 | 137 | NOTICE OF SERVICE of Plaintiffs' Final Election of Asserted Claims Served on Mylan Pharmaceuticals Inc. -- filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/05/2023) (5) |
| Aug 25, 2023 | 127 | NOTICE to Take Deposition of Jesper Lau on October 2, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (5) |
| Aug 25, 2023 | 128 | NOTICE to Take Deposition of Tom Hede Markussen on September 21, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (4) |
| Aug 25, 2023 | 129 | NOTICE to Take Deposition of Christine Bjoern Jensen on October 11, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (5) |
| Aug 25, 2023 | 130 | NOTICE to Take Deposition of Claus Mller on September 20, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (4) |
| Aug 25, 2023 | 131 | NOTICE to Take Deposition of Thomas Kruse Hansen on October 4, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (5) |
| Aug 25, 2023 | 132 | NOTICE to Take Deposition of Christian Peter Enggaard on September 22, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (5) |
| Aug 25, 2023 | 133 | NOTICE to Take Deposition of Dorthe Kot Engelund on October 17, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (3) |
| Aug 25, 2023 | 134 | NOTICE to Take Deposition of Florencio Doerwald on October 9, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (3) |
| Aug 25, 2023 | 135 | NOTICE to Take Deposition of Tina Bjeldskov Pedersen on October 16, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (3) |
| Aug 25, 2023 | 136 | NOTICE to Take Deposition of Paw Bloch on October 6, 2023 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/25/2023) (5) |
| Aug 24, 2023 | 126 | REDACTED VERSION of (124 in 1:22-cv-01040-CFC, 162 in 1:22-md-03038-CFC) Notice to Take Deposition by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/24/2023) (8) |
| Aug 22, 2023 | 125 | NOTICE OF SERVICE of Defendants' Final Election of Asserted Prior Art filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/22/2023) (2) |
| Aug 17, 2023 | 124 | [SEALED] NOTICE to Take Deposition of Mylan Pharmaceuticals Inc. on September 11, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/17/2023) (0) |
| Aug 16, 2023 | 123 | OBJECTIONS by Novo Nordisk A/S, Novo Nordisk Inc. -- Plaintiffs' Answer to Mylan Pharmaceuticals Inc.'s First Amended Counterclaims to First Amended Complaint -- (linked to 117 in 1:22-cv-01040-CFC; 154 in 1:22-md-03038-CFC). (Murray, Travis) (Entered: 08/16/2023) (30) |
| Aug 11, 2023 | 122 | NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.s Supplemental Initial Disclosures Pursuant to the Delaware Default Standard for Discovery and (2) Mylan Pharmaceuticals Inc.s Supplemental Initial Disclosures Under Fed. R. Civ. P. 26(a)(1) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/11/2023) (2) |
| Aug 8, 2023 | 120 | ORDER re (156 in 1:22-md-03038-CFC) Letter. Setting Deadlines/Hearings: Expert Witness List due by 10/20/2023. Joint Claim Construction Brief due by 11/20/2023. A Markman Hearing is set for 12/4/2023 at 10:00 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 8/8/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 08/08/2023) (2) |
| Aug 8, 2023 | 121 | NOTICE to Take Deposition of Corporate 30(b)(6) Designee filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/08/2023) (18) |
| Aug 4, 2023 | 119 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding the Court's July 25, 2023 Claim Construction Order - re (113 in 1:22-cv-01040-CFC, 158 in 1:22-cv-00294-CFC, 148 in 1:22-md-03038-CFC) Order,. (Murray, Travis) (Entered: 08/04/2023) (4) |
| Aug 3, 2023 | 118 | NOTICE OF SERVICE of Novo Nordisk's First Amended Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/03/2023) (12) |
| Aug 2, 2023 | 116 | SO ORDERED, re (152 in 1:22-md-03038-CFC, 115 in 1:22-cv-01040-CFC) Stipulation to Amend Answer and Counterclaims, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 8/2/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC (kmd) (Entered: 08/02/2023) (4) |
| Aug 2, 2023 | 117 | ANSWER to Amended Complaint, re: 84 Amended Complaint (Amended), COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/02/2023) (30) |
| Aug 1, 2023 | 115 | STIPULATION to Amend Answer and Counterclaims by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Stamoulis, Stamatios) (Entered: 08/01/2023) (0) |
| Jul 31, 2023 | 114 | NOTICE OF SERVICE of (1) Plaintiffs' Second Amended Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Plaintiffs' Third Amended Disclosures to Defendants Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 07/31/2023) (5) |
| Jul 25, 2023 | 113 | CLAIM CONSTRUCTION ORDER re (147 in 1:22-md-03038-CFC, 157 in 1:22-cv-00294-CFC, 112 in 1:22-cv-01040-CFC) Proposed Claim Construction Order. Signed by Judge Colm F. Connolly on 7/25/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(nmf) (Entered: 07/25/2023) (8) |
| Jul 20, 2023 | 112 | PROPOSED ORDER -- Claim Construction -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 07/20/2023) (8) |
| Jul 17, 2023 | 111 | Official Transcript of Markman Hearing held on July 13, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 8/7/2023. Redacted Transcript Deadline set for 8/17/2023. Release of Transcript Restriction set for 10/16/2023. (nmf) (Entered: 07/17/2023) (134) |
| Jul 12, 2023 | 109 | SO ORDERED, re (142 in 1:22-md-03038-CFC, 154 in 1:22-cv-00294-CFC, 107 in 1:22-cv-01040-CFC) Joint MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 7/12/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 07/12/2023) (6) |
| Jul 12, 2023 | 110 | MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 07/12/2023) (4) |
| Jul 11, 2023 | 107 | Joint MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 07/11/2023) (6) |
| Jul 11, 2023 | 108 | NOTICE of Withdrawal of Michael R. Laing as Counsel by Mylan Pharmaceuticals Inc. (Stamoulis, Stamatios) (Entered: 07/11/2023) (2) |
| Jun 26, 2023 | 106 | NOTICE OF SERVICE of (1) Plaintiffs' First Amended Disclosures to Defendant Mylan Pharmaceuticals Inc. Under Paragraph 3 of the District of Delaware Default Standard and (2) Plaintiffs' Second Amended Disclosures to Defendant Mylan Pharmaceuticals Inc. Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/26/2023) (5) |
| Jun 23, 2023 | 104 | STIPULATION TO EXTEND TIME Joint Stipulation Extending Deadline for Substantial Completion of Document Production to June 30, 2023 - filed by EMS S/A, Rio Biopharmaceuticals, Inc.. (Dorsney, Kenneth) (Entered: 06/23/2023) (6) |
| Jun 23, 2023 | 105 | SO ORDERED, re (104 in 1:22-cv-01040-CFC, 138 in 1:22-md-03038-CFC, 151 in 1:22-cv-00294-CFC) STIPULATION TO EXTEND TIME Joint Stipulation Extending Deadline for Substantial Completion of Document Production to June 30, 2023, filed by Rio Biopharmaceuticals, Inc., EMS S/A. Setting Scheduling Order Deadlines: Discovery due by 6/30/2023. Signed by Judge Colm F. Connolly on 6/23/2023. Associated Cases: 1:22-cv-01040-CFC, 1:22-cv-00294-CFC, 1:22-md-03038-CFC (kmd) (Entered: 06/23/2023) (6) |
| May 30, 2023 | 103 | SO ORDERED, re (133 in 1:22-md-03038-CFC, 146 in 1:22-cv-00294-CFC, 102 in 1:22-cv-01040-CFC) STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to June 23, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Setting Deadlines: Discovery due by 6/23/2023. Signed by Judge Colm F. Connolly on 5/30/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 05/30/2023) (5) |
| May 26, 2023 | 102 | STIPULATION TO EXTEND TIME for Substantial Completion of Document Production to June 23, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/26/2023) (5) |
| May 23, 2023 | 101 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/23/2023) (30) |
| May 19, 2023 | 100 | STIPULATION and [Proposed] Order to Extend the Deadline to Submit Amended Joint Claim Construction Chart to and including May 23, 2023 by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/19/2023) (5) |
| May 15, 2023 | 99 | SO ORDERED, re (98 in 1:22-cv-01040-CFC, 141 in 1:22-cv-00294-CFC, 128 in 1:22-md-03038-CFC) STIPULATION TO EXTEND TIME to submit an amended joint claim construction chart to May 19, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/15/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-00294-CFC, 1:22-cv-01040-CFC(nmf) (Entered: 05/15/2023) (4) |
| May 12, 2023 | 98 | STIPULATION TO EXTEND TIME to submit an amended joint claim construction chart to May 19, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/12/2023) (4) |
| May 10, 2023 | 97 | OBJECTIONS by Novo Nordisk A/S, Novo Nordisk Inc. to (89 in 1:22-cv-01040-CFC, 89 in 1:22-cv-01040-CFC) Answer to Amended Complaint, Counterclaim // Plaintiffs' Answer to Mylan Pharmaceuticals Inc.'s Counterclaims to First Amended Complaint. (Murray, Travis) (Entered: 05/10/2023) (30) |
| May 8, 2023 | 96 | REDACTED VERSION of (137 in 1:22-cv-00294-CFC, 123 in 1:22-md-03038-CFC, 95 in 1:22-cv-01040-CFC) Appendix, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-L, # 2 Exs. 1-14)(Murray, Travis) (Entered: 05/08/2023) (Main Document) (13) |
| May 8, 2023 | 96 | REDACTED VERSION of (137 in 1:22-cv-00294-CFC, 123 in 1:22-md-03038-CFC, 95 in 1:22-cv-01040-CFC) Appendix, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-L, # 2 Exs. 1-14)(Murray, Travis) (Entered: 05/08/2023) (Exs. A-L) (30) |
| May 8, 2023 | 96 | REDACTED VERSION of (137 in 1:22-cv-00294-CFC, 123 in 1:22-md-03038-CFC, 95 in 1:22-cv-01040-CFC) Appendix, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-L, # 2 Exs. 1-14)(Murray, Travis) (Entered: 05/08/2023) (Exs. 1-14) (30) |
| May 5, 2023 | 95 | [SEALED] Joint APPENDIX re (119 in 1:22-md-03038-CFC) Joint Claim Construction Brief, (91 in 1:22-cv-01040-CFC) Joint Claim Construction Brief, (136 in 1:22-cv-00294-CFC) Joint Claim Construction Brief - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-L, # 2 Exs. 1-14)(Murray, Travis) (Entered: 05/05/2023) (0) |
| May 2, 2023 | 93 | STIPULATION TO EXTEND TIME for Novo Nordisk Inc. and Novo Nordisk A/S to respond to Mylan Pharmaceuticals Inc.'s Answer, Separate Defenses, and Counterclaims to First Amended Complaint to May 10, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/02/2023) (3) |
| May 2, 2023 | 94 | SO ORDERED, re (93 in 1:22-cv-01040-CFC, 121 in 1:22-md-03038-CFC) STIPULATION TO EXTEND TIME for Novo Nordisk Inc. and Novo Nordisk A/S to respond to Mylan Pharmaceuticals Inc.'s Answer, Separate Defenses, and Counterclaims to First Amended Complaint to May 10, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/2/2023. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 05/02/2023) (3) |
| May 1, 2023 | 91 | JOINT CLAIM CONSTRUCTION BRIEF - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/01/2023) (30) |
| Apr 27, 2023 | 90 | NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/27/2023) (2) |
| Apr 12, 2023 | 89 | ANSWER to Amended Complaint, re: 84 Amended Complaint , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/12/2023) (30) |
| Apr 6, 2023 | 88 | NOTICE OF SERVICE of (1) Novo Nordisk's Reply Claim Construction Brief and (2) Declaration of Laura T. Moran in Support of Novo Nordisk A/S and Novo Nordisk Inc.'s Reply Claim Construction Brief - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/06/2023) (12) |
| Apr 4, 2023 | 87 | STIPULATION TO EXTEND TIME to Respond to Amended Complaint to April 12, 2023 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 04/04/2023) (3) |
| Mar 22, 2023 | 85 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than February 13, 2023 (as to Mylan Pharmaceuticals, Inc.'s ANDA No. 217706 added to the case in Plaintiffs' First Amended Complaint). Date of Expiration of Patent: U.S. Patent No. 8,114,833 expires on 8/13/2025; U.S. Patent Nos. 8,684,969 and 11,446,443 expire on 10/20/2025; U.S. Patent Nos. 9,108,002, 9,616,180, 9,861,757, 10,357,616, 10,376,652, and 11,311,679 expire on 1/20/2026; U.S. Patent No. 8,536,122 expires on 3/20/2026; Patent No. RE46,363 expires on 8/3/2026; U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and 11,097,063 expire on 7/17/2026; U.S. Patent No. 9,457,154 expires on 9/27/2027; U.S. Patent No. 9,132,239 expires on 2/1/2032; U.S. Patent No. 8,129,343 expires on 12/5/2031.Thirty Month Stay Deadline: 8/13/2025. (Murray, Travis) (Entered: 03/22/2023) (2) |
| Mar 22, 2023 | 86 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,114,833; 8,129,343; 8,536,122; ;8,684,969; 8,920,383; 9,108,002; ;9,132,239; 9,457,154; 9,616,180; ;9,687,611; 9,775,953; 9,861,757; ;10,220,155; 10,335,462; 10,357,616; ;10,376,652; 11,097,063; 11,311,679; ;11,446,443; and RE46,363 . (Murray, Travis) (Entered: 03/22/2023) (2) |
| Mar 21, 2023 | 84 | Amended Complaint* (1) |
| Nov 30, 2022 | 57 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s First Supplemental Objections and Responses to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-10) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/30/2022) (2) |
| Nov 22, 2022 | 56 | NOTICE OF SERVICE of (1) Plaintiffs' Response to Defendants' First Set of Interrogatories (Nos. 1-4); and (2) Plaintiffs' Response to Defendants' First Set of Requests for Production (Nos. 1-23) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/22/2022) (11) |
| Nov 16, 2022 | 55 | NOTICE OF SERVICE of Plaintiffs' Second Set of Collective Interrogatories to Defendants (No. 13) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/16/2022) (11) |
| Nov 10, 2022 | 54 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s Objections and Responses to First Set of Collective Interrogatories (Nos. 1-12) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/10/2022) (2) |
| Nov 9, 2022 | 53 | SO ORDERED, re (52 in 1:22-cv-01040-CFC, 52 in 1:22-md-03038-CFC) PROPOSED ORDER Adopting Scheduling Order, Protective Order and ESI Order. Signed by Judge Colm F. Connolly on 11/9/2022. (nmf) (Entered: 11/09/2022) (4) |
| Nov 4, 2022 | 52 | PROPOSED ORDER Adopting Scheduling Order, Protective Order and ESI Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 11/04/2022) (4) |
| Oct 27, 2022 | 51 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s Objections and Responses to Plaintiffs Second Set of Requests for the Production of Documents and Things (Nos. 11-162) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 10/27/2022) (2) |
| Oct 21, 2022 | 50 | NOTICE OF SERVICE of Defendants First Set of Interrogatories to Plaintiffs and Defendants First Set of Requests for Production to Plaintiffs filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 10/21/2022) (2) |
| Oct 20, 2022 | 48 | NOTICE OF SERVICE of Defendants Initial Invalidity Contentions filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 10/20/2022) (2) |
| Oct 20, 2022 | 49 | NOTICE OF SERVICE of Defendants Noninfringement Contentions filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 10/20/2022) (2) |
| Oct 11, 2022 | 47 | NOTICE OF SERVICE of Plaintiffs' First Set of Collective Interrogatories to Defendants (Nos. 1-12) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/11/2022) (5) |
| Sep 27, 2022 | 46 | NOTICE OF SERVICE of Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 11-162) Directed to Defendant Mylan Pharmaceuticals, Inc. - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/27/2022) (5) |
| Sep 9, 2022 | 45 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s Objections and Responses to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-10) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | N/A | Pro Hac Vice Attorney Shannon M. Bloodworth for Mylan Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 09/07/2022) (0) |
| Sep 7, 2022 | N/A | Pro Hac Vice Attorney Bryan D. Beel for Mylan Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 09/07/2022) (0) |
| Aug 30, 2022 | N/A | SO ORDERED, re (17 in 1:22-md-03038-CFC, 44 in 1:22-cv-01040-CFC) MOTION for Pro Hac Vice Appearance of Attorney Jonathan I. Tietz, Shannon M. Bloodworth, Emily J. Greb, Michael R. Laing, and Bryan D. Beel, Ph.D., filed by Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 8/30/2022. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 08/30/2022) (0) |
| Aug 29, 2022 | 44 | MOTION for Pro Hac Vice Appearance of Attorney Jonathan I. Tietz, Shannon M. Bloodworth, Emily J. Greb, Michael R. Laing, and Bryan D. Beel, Ph.D. - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 08/29/2022) (8) |
| Aug 26, 2022 | 42 | NOTICE OF SERVICE of (1) Plaintiffs' Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Plaintiffs' Preliminary Disclosure of Asserted Patents and Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 08/26/2022) (3) |
| Aug 26, 2022 | 43 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s Initial Disclosures Pursuant to the Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/26/2022) (2) |
| Aug 25, 2022 | 40 | NOTICE of Appearance by Stamatios Stamoulis on behalf of Mylan Pharmaceuticals Inc. (Stamoulis, Stamatios) (Entered: 08/25/2022) (2) |
| Aug 25, 2022 | 41 | NOTICE of Appearance by Richard Charles Weinblatt on behalf of Mylan Pharmaceuticals Inc. (Weinblatt, Richard) (Entered: 08/25/2022) (2) |
| Aug 22, 2022 | 39 | MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, Erica R. Sutter and Olivia L. Wheeling - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/22/2022) (12) |
| Aug 22, 2022 | N/A | SO ORDERED, re (39 in 1:22-cv-01040-CFC, 11 in 1:22-md-03038-CFC) MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, Erica R. Sutter and Olivia L. Wheeling, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 8/22/2022. Associated Cases: 1:22-md-03038-CFC, 1:22-cv-01040-CFC(kmd) (Entered: 08/22/2022) (0) |
| Aug 12, 2022 | 38 | NOTICE OF SERVICE of Plaintiffs' Amended Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/12/2022) (3) |
| Aug 10, 2022 | 37 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-10) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/10/2022) (3) |
| Aug 8, 2022 | 35 | Record of case transferred in from District of West Virginia Northern; Case Number in Other District: 1:22-cv-00023. Copy of Docket Sheet and original file (Entered: 08/08/2022) (Main Document Public Docket Sheet) (8) |
| Aug 8, 2022 | N/A | NOTICE TO COUNSEL: MDL No. 1:2022-md-3038 has been opened and assigned to the Honorable Colm F. Connolly. Attorneys of record who will be electronically filing documents may request E-Filing rights through PACER and add the MDL case number in the comments section of your request. Please see the docket for further entries. (smg) (Entered: 08/08/2022) (0) |
| Aug 8, 2022 | N/A | NOTICE: Documents relating to all actions should be filed on the master docket sheet and on the docket sheet of each individual action. Documents relating to two or more, but not all, individual actions should be filed on the master docket sheet, and on the docket sheet of each affected individual action. Documents affecting a single individual action should be filed on the docket sheet of that action and on the master docket sheet. (smg) (Entered: 08/08/2022) (0) |
| Aug 8, 2022 | 36 | NOTICE of Appearance by Brian P. Egan on behalf of Novo Nordisk A/S, Novo Nordisk Inc. (Egan, Brian) (Entered: 08/08/2022) (6) |
| Aug 5, 2022 | 34 | CERTIFIED COPY OF JPML CONDITIONAL TRANSFER ORDER re: pldg. ( 1 in MDL No. 3038) Transferring 1 action(s) to Judge Colm F. Connolly in the D. Delaware. Signed by Judge Karen K. Caldwell, Chair, PANEL ON MULTIDISTRICT LITIGATION, on 8/5/2022. Associated Cases: MDL No. 3038, DE/1:22-cv-00294, DE/1:22-cv-00296, DE/1:22-cv-00297, DE/1:22-cv-00298, DE/1:22-cv-00299, WVN/1:22-cv-00023. (jmm) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 08/05/2022) (5) |
| Aug 5, 2022 | N/A | Case transferred to the District of Delaware re MDL 3038. Entire Case file electronically transmitted. (jmm) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 08/05/2022) (0) |
| May 24, 2022 | 30 | CERTIFICATE OF SERVICE by Novo Nordisk, A/S Plaintiffs' Disclosure Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure (Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/24/2022) (2) |
| May 24, 2022 | 31 | Pro Hac Vice Filing fee for E. Sutter and O. Wheeling: $ 400.00, receipt number WVNC003450. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/24/2022) (0) |
| May 24, 2022 | 32 | ORDER granting 28 Motion of Erica Sutter for Leave to Appear Pro Hac Vice on behalf of Novo Nordisk, A/S, Novo Nordisk, Inc. Signed by District Judge John Preston Bailey on 5/24/2022. (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/24/2022) (1) |
| May 24, 2022 | 33 | ORDER granting 29 Motion of Olivia L. Wheeling for Leave to Appear Pro Hac Vice on behalf of Novo Nordisk, A/S, Novo Nordisk, Inc. Signed by District Judge John Preston Bailey on 5/24/2022. (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/24/2022) (1) |
| May 19, 2022 | 28 | MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Continued page for Application for Admission, # 2 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/19/2022) (Main Document) (2) |
| May 19, 2022 | 29 | MOTION for Leave to Appear Pro Hac Vice of Olivia L. Wheeling by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/19/2022) (Main Document) (2) |
| May 19, 2022 | 29 | MOTION for Leave to Appear Pro Hac Vice of Olivia L. Wheeling by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/19/2022) (Proposed Order) (1) |
| May 19, 2022 | 28 | MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Continued page for Application for Admission, # 2 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/19/2022) (Attachment Continued page for Application for Admission) (1) |
| May 19, 2022 | 28 | MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Continued page for Application for Admission, # 2 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/19/2022) (Proposed Order) (1) |
| May 16, 2022 | 27 | REPORT of Rule 26(f) Planning Meeting. (White, Brandon) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/16/2022) (22) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Main Document) (3) |
| May 11, 2022 | 26 | NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Pharmaceuticals, Inc. (Copland, Gordon) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (2) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 1 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 2 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 3 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 4 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 5 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Exhibit 6 to Corrected Schedule of Actions) (30) |
| May 11, 2022 | 25 | Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Exhibit 1 to Corrected Schedule of Actions, # 2 Exhibit 2 to Corrected Schedule of Actions, # 3 Exhibit 3 to Corrected Schedule of Actions, # 4 Exhibit 4 to Corrected Schedule of Actions, # 5 Exhibit 5 to Corrected Schedule of Actions, # 6 Exhibit 6 to Corrected Schedule of Actions, # 7 Attachment Corrected Proof of Service)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/11/2022) (Attachment Corrected Proof of Service) (4) |
| May 9, 2022 | 23 | Joint MOTION for Extension of Deadline to File the Joint Report of Initial Planning Meeting by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/09/2022) (Main Document) (3) |
| May 9, 2022 | 24 | ORDER EXTENDING DEADLINE re 23 . The Court hereby ORDERS that the parties may submit their Joint Report of Initial Planning Meeting through and until May 16, 2022. Signed by District Judge John Preston Bailey on 5/9/2022. (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/09/2022) (1) |
| May 9, 2022 | 23 | Joint MOTION for Extension of Deadline to File the Joint Report of Initial Planning Meeting by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/09/2022) (Proposed Order) (1) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Main Document) (7) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Attachment Opening Brief to Motion to Transfer) (21) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Attachment Schedule of Actions) (2) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 1 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 2 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 3 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 4 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 5 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Exhibit 6 to Schedule of Actions) (30) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Attachment Proof of Service) (4) |
| May 6, 2022 | 22 | Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Attachment Opening Brief to Motion to Transfer, # 2 Attachment Schedule of Actions, # 3 Exhibit 1 to Schedule of Actions, # 4 Exhibit 2 to Schedule of Actions, # 5 Exhibit 3 to Schedule of Actions, # 6 Exhibit 4 to Schedule of Actions, # 7 Exhibit 5 to Schedule of Actions, # 8 Exhibit 6 to Schedule of Actions, # 9 Attachment Proof of Service, # 10 Attachment Oral Argument Statement)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 05/06/2022) (Attachment Oral Argument Statement) (2) |
| Apr 29, 2022 | 21 | PLAINTIFFS' ANSWER to 19 Answer to Complaint, Counterclaim by Novo Nordisk, A/S, Novo Nordisk, Inc..(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 04/29/2022) (30) |
| Apr 8, 2022 | 19 | ANSWER to 2 Complaint,, , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals, Inc..(White, Brandon) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 04/08/2022) (30) |
| Apr 8, 2022 | 20 | Corporate Disclosure Statement by Mylan Pharmaceuticals, Inc.. (White, Brandon) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 04/08/2022) (2) |
| Mar 29, 2022 | 15 | ORDER granting 9 Motion for Leave to Appear Pro Hac Vice of Laura Moran. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/29/2022) (1) |
| Mar 29, 2022 | 16 | ORDER granting 10 Motion for Leave to Appear Pro Hac Vice of Robert Counihan. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/29/2022) (1) |
| Mar 29, 2022 | 17 | ORDER granting 11 Motion for Leave to Appear Pro Hac Vice of Jeffrey Oelke. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/29/2022) (1) |
| Mar 29, 2022 | 18 | ORDER granting 12 Motion for Leave to Appear Pro Hac Vice of Ryan Johnson. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/29/2022) (1) |
| Mar 28, 2022 | 8 | FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 4/25/2022. Rule 26 Meeting Report due by 5/9/2022. Discovery due by 5/23/2022. Signed by District Judge John Preston Bailey on 3/28/2022. (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (4) |
| Mar 28, 2022 | 9 | MOTION for Leave to Appear Pro Hac Vice of Laura Moran by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Main Document) (2) |
| Mar 28, 2022 | 10 | MOTION for Leave to Appear Pro Hac Vice of Robert Counihan by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Main Document) (2) |
| Mar 28, 2022 | 11 | MOTION for Leave to Appear Pro Hac Vice of Jeffrey Oelke by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Main Document) (2) |
| Mar 28, 2022 | 12 | MOTION for Leave to Appear Pro Hac Vice of Ryan Johnson by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Main Document) (2) |
| Mar 28, 2022 | 13 | WAIVER OF SERVICE Returned Executed by Novo Nordisk, A/S, Novo Nordisk, Inc.. Mylan Pharmaceuticals, Inc. waiver sent on 3/24/2022, answer due 5/23/2022. (Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (1) |
| Mar 28, 2022 | 14 | Pro Hac Vice filing fee: $ 800.00, receipt number WVNC003403 as to attorneys L. Morgan, R. Johnson, J. Oelke, and R. Counihan. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (0) |
| Mar 28, 2022 | 11 | MOTION for Leave to Appear Pro Hac Vice of Jeffrey Oelke by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Proposed Order) (1) |
| Mar 28, 2022 | 10 | MOTION for Leave to Appear Pro Hac Vice of Robert Counihan by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Proposed Order) (1) |
| Mar 28, 2022 | 9 | MOTION for Leave to Appear Pro Hac Vice of Laura Moran by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Proposed Order) (1) |
| Mar 28, 2022 | 12 | MOTION for Leave to Appear Pro Hac Vice of Ryan Johnson by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # 1 Proposed Order)(Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/28/2022) (Proposed Order) (1) |
| Mar 25, 2022 | 7 | ORDER. Case reassigned to District Judge John Preston Bailey for all further proceedings. Senior Judge Irene M. Keeley no longer assigned to case. Signed by Senior Judge Irene M. Keeley on 03/25/2022. (kam) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/25/2022) (1) |
| Mar 18, 2022 | 1 | REPORT ON FILING ACTION RE PATENT Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (2) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Main Document) (25) |
| Mar 18, 2022 | 3 | REPORT to USPTO on the filing or determination of an action regarding re 2 Complaint. (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (2) |
| Mar 18, 2022 | 4 | VERIFICATION OF ATTORNEY ADMISSION to Attorneys J. Oelke, L. Moran, R. Johnson, and R. Counihan. (to Oelke, Moran, and Johnson by NEF; to R. Counihan by U.S. mail) (dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (1) |
| Mar 18, 2022 | 5 | Disclosure Statement Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (2) |
| Mar 18, 2022 | 6 | Supplemental ANDA Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (2) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit A - 833 Patent) (23) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit B - 343 Patent) (30) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit C - 122 Patent) (30) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit D - 969 Patent) (14) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit E - 383 Patent) (15) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit F - 002 Patent) (20) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit G - 239 Patent) (9) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit H - 154 Patent) (25) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit I - 180 Patent) (21) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit J - 611 Patent) (13) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit K - 953 Patent) (16) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit L - 757 Patent) (23) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit M - 155 Patent) (7) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit N - 462 Patent) (26) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit O - 616 Patent) (24) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit P - 652 Patent) (21) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit Q - 063 Patent) (7) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Exhibit R - 363 Patent) (16) |
| Mar 18, 2022 | 2 | COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # 1 Exhibit A - 833 Patent, # 2 Exhibit B - 343 Patent, # 3 Exhibit C - 122 Patent, # 4 Exhibit D - 969 Patent, # 5 Exhibit E - 383 Patent, # 6 Exhibit F - 002 Patent, # 7 Exhibit G - 239 Patent, # 8 Exhibit H - 154 Patent, # 9 Exhibit I - 180 Patent, # 10 Exhibit J - 611 Patent, # 11 Exhibit K - 953 Patent, # 12 Exhibit L - 757 Patent, # 13 Exhibit M - 155 Patent, # 14 Exhibit N - 462 Patent, # 15 Exhibit O - 616 Patent, # 16 Exhibit P - 652 Patent, # 17 Exhibit Q - 063 Patent, # 18 Exhibit R - 363 Patent, # 19 Civil Cover Sheet)(dk) [Transferred from West Virginia Northern on 8/8/2022.] (Entered: 03/18/2022) (Civil Cover Sheet) (2) |
